Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

High-throughout sequencing of colorectal cancer and non-small cell lung cancer cells treated actived compound YHM18

ABSTRACT: High-throughout sequencing of colorectal cancer and non-small cell lung cancer cells treated actived compound YHM18

PROVIDER: PRJNA1008574 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

High-throughout sequencing of colorectal cancer and non-small cell lung cancer cells treated actived compound YHM18

Project description:The high-throughput sequencing technology was performed after the treatment of human colorectal cancer cells HCT116 and non-small cell lung cancer cells A549 with the active compound YHM18 designed and synthesized by ourselves, to explore the expression of genes related to cell proliferation, adhesion, migration and invasion of human colorectal cancer cells HCT116 and non-small cell lung cancer cells A549 after the treatment of the active compound and to find an interesting target gene, GTSE1.

2024-11-11 | GSE241518 | GEO

High-throughout sequencing of triple negative breast cancer cells treated actived compound D16

Project description:High-throughout sequencing of triple negative breast cancer cells treated actived compound D16

| PRJNA754393 | ENA

Gene expression of colorectal cancer cells treated with Celastrol or compound 19-048

Project description:As a terpenoids natural product isolated from the plant Thunder God Vine, Celastrol is widely studied for its pharmacological activities, including anti-tumor activities. However, the clinical application of Celastrol is strictly limited due to its severe side effects. Without identification and validation of the target protein of Celastrol, it is difficult to determine whether its anti-tumor activities and side effects are due to inhibition of the same protein. Using a new computational tool we have developed for target discovery, peroxiredoxin I (PRDX1) was identified as the ROS-manipulating target protein of Celastrol. High-resolution crystal structure revealed the unique binding mode of Celastrol with PRDX1, via covalent reaction to the catalytic Cys-173 residue of PRDX1. New derivative compound named 19-048 with improved potency against PRDX1 and selectivity towards PRDX2~PRDX6 were synthesized. Both Celastrol and compound 19-048 effectively suppressed the proliferation of colorectal cancer cells. While these anti-tumor efficacy was significantly diminished on xenograft nude mice bearing PRDX1 knock-down colorectal cancer cells. Several downstream genes of p53 were dramatically up-regulated in the presence of Celastrol and compound 19-048. Our findings reveal that the side effects of Celastrol could be reduced via structural modification, and PRDX1 inhibition is promising for the treatment of colorectal cancer.

2022-12-31 | GSE198630 | GEO

Colorectal cancer

Project description:Colorectal cancer

| PRJNA774637 | ENA

Colorectal cancer

Project description:Colorectal cancer

| PRJNA836954 | ENA

High-throughout sequencing of triple negative breast cancer cells treated actived compound D16

Project description:The high-throughput sequencing technology was performed after the treatment of human triple negative breast cancer cells MDA-MB-231 with the active compound D16 designed and synthesized by ourselves, to explore the expression of genes related to cell proliferation, adhesion, migration and invasion of human triple negative breast cancer cells MDA-MB-231 after the treatment of the active compound Changes to explore the effect of active compounds on the proliferation and motility of triple breast breast cancer cells and to find an interesting target gene, CKAP2.

2021-08-17 | GSE182063 | GEO

Gene expression of colorectal cancer cells treated with Celastrol or compound 19-048

Project description:Gene expression of colorectal cancer cells treated with Celastrol or compound 19-048

| PRJNA816185 | ENA

New therapy for colorectal cancer targeting cancer metabolism through serotonin receptor HTR2B

Project description:Serotonin is important material in our body. 5-HT is synthesized by TPH1 starting with tryptophan and this compound exists on colorectal cancer. And serotonin combines with various receptors to conduct the metabolic pathway in colorectal cancer. Each receptor relates with various metabolism, such as lipid metabolism, growth, immunity, etc. In this way, medicine which inhibits these receptors can expect for therapy of colorectal cancer. Especially HTR 2B has correlation with growth factor and using the inhibitor of HTR2B, SB204741, can have effect on metabolic pathway in colorectal cancer. So, we set the hypothesis that HTR2B antagonist can have negative effect on growth of colorectal cancer.

2024-03-12 | GSE260979 | GEO

OncoArray: Colorectal Cancer

Project description:OncoArray: Colorectal Cancer

| PRJNA573761 | ENA

OncoArray: Colorectal Cancer

Project description:OncoArray: Colorectal Cancer

| PRJNA573762 | ENA